Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H19O5S.Na |
Molecular Weight | 370.395 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])C2=CCC4=C3C=CC(OS([O-])(=O)=O)=C4
InChI
InChIKey=QTTMOCOWZLSYSV-QWAPEVOJSA-M
InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1
Equilin sulfate is one of the main component, which is responsible for the pharmacological action of the PREMARIN, conjugated estrogens tablets. Premarin is used to treat the moderate to severe vasomotor symptoms, vulvar and vaginal atrophy due to menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure; to treat breast cancer and advanced androgen-dependent carcinoma of the prostate (for Palliation Only). In addition, premarin is used to prevent postmenopausal osteoporosis. Equilin sulfate is a prodrug, which is hydrolyzed to the corresponding free estrogen equilin, an inhibitor of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). Human 17beta-HSD1 catalyzes the reduction of inactive estrone (E1) to the active 17beta-estradiol in breast tissues, is a key enzyme responsible for elevated levels of E2 in breast tumor tissues. Thus equilin reduce the E2 levels in breast tissues and hence the reduce risk of estrogen-dependent breast cancer.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PREMARIN Approved Use1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis. |
|||
Primary | PREMARIN Approved Use1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis. |
|||
Primary | PREMARIN Approved Use1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis. |
|||
Primary | PREMARIN Approved Use1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis. |
|||
Preventing | PREMARIN Approved Use1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3338581
In order to determine the relative potency of equilin sulfate (EqS) 15 women received oral doses of EqS (0.15, 0.31, and 0.625 mg) for 25 days. Doses of 0.31 and 0.625 mg significantly stimulated hepatic globulins. This stimulatory effect ranged from being 1.5 to 8 times greater than the effects of comparable doses of estrone sulfate and conjugated equine estrogens.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2293
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB13695MIG
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
100000086283
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
7XY8FW3E68
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
C61941
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
Sodium equilin sulfate
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
23676225
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
DTXSID00872961
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
240-727-2
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
16680-47-0
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD